Substituted cycloalkenopyrazoles as BUB1 inhibitors for the treatment of cancer

US9416125B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Marion Hitchcock · Berlin, DE
• Christoph-Stephan Hilger · Berlin, DE
• Anne Mengel · Berlin, DE
• Hans Briem · Bremen, DE
• Simon Holton · Berlin, DE
• Vera Pütter · Berlin, DE
• Gerhard Siemeister · Berlin, DE
• Stefan Prechtl · Berlin, DE
• Amaury Ernesto Fernandez-Montalvan · Leverkusen, DE
• Christian Stegmann · Berlin, DE
• Cornelia PREUßE · Berlin, DE
• Mark Jean Gnoth · Mettmann, DE

Key dates

• Filing date: May 8, 2013
• Grant date: Aug 16, 2016
• Expiry date: May 8, 2033

Classification

• Technology area (CPC —): General

Abstract

Compounds of formula (I), processes for their production and their use as Bub1 kinase inhibitors for the treatment of hyperproliferative diseases and/or disorders responsive to induction of cell death.